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ARTICLES
Interleukin-8 and development of adult respiratory
distress syndrome in at-risk patient groups
Neutrophils have been implicated in the
pathogenesis of the adult respiratory distress
syndrome (ARDS). We have measured
concentrations of the neutrophil attractant
interleukin-8 in blood and bronchoalveolar lavage
fluid (BAL) from patients at risk of ARDS.
We studied 29 patients from three groups at risk of
developing ARDS: multiple trauma (n=16),
perforated bowel (n=6), and pancreatitis (n=7).
ARDS developed in 7 of these patients. Interleukin-8
in BAL and blood samples taken on initial hospital
presentation was measured by a sandwich enzyme-
linked immunosorbent assay. The mean BAL
interleukin-8 concentration was significantly higher
for the patients who subsequently progressed to
ARDS than for the non-ARDS group (3&middot;06 [SE
2&middot;64] vs 0&middot;053 [0&middot;010] ng/mL, p=0&middot;0006). There
was no difference between the groups in plasma
interleukin-8 (6&middot;23 [2&middot;60] vs 5&middot;12 [2&middot;22] ng/mL,
p=0&middot;31). Immunocytochemistry suggested that the
alveolar macrophage is an important source of
interleukin-8 at this early stage in ARDS
development.
This study provides evidence of a relation between
the presence of interleukin-8 in early BAL samples
and the development of AR DS. The early appearance
of interleukin-8 in BAL of patients at risk of ARDS
may be an important prognostic indicator for the
development of the disorder and reinforces the likely
importance of neutrophils and the effects of their
accumulation and activation in the pathogenesis of
many cases of ARDS.
Introduction
Adult respiratory distress syndrome (ARDS)
characteristically develops after a latent period of hours or
days since the initiating or provoking insult. The
progressive respiratory failure is associated with
pathological features caused by the breakdown of alveolar
capillary integrity within the lung and leakage of protein-
rich fluid into the alveolar space. Despite improvements in
intensive care support for patients with ARDS, mortality
has remained at 50-90%.1 Research has tended to
concentrate on patients with established ARDS in an
intensive care setting. However, the disease process is likely
to have been under way for hours or days before clinical
presentation. The risk of progression to ARDS varies from
1% to 35 %, depending on the initiating or provoking
insult.2 At present it is not possible to identify clearly
individuals or subgroups of patients who are at very high
risk of this disorder.
It is generally believed that ARDS arises as a result of
tissue injury secondary to inflammatory-cell sequestration,
emigration, activation, and secretion of their histotoxic
products. Neutrophils have received much attention as a key
part of this process.3 Although ARDS has been described in
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patients with peripheral-blood neutropenia, there is
evidence implicating neutrophils specifically in most cases
of ARDS. Histology of lung samples from ARDS patients
shows an intense inflammatory infiltrate within the
interstitium, which is predominantly neutrophilic.4
Dynamic studies in vivo with radiolabelling techniques
showed increased localisation of neutrophils within the lung
in active ARDS.5 Analysis of bronchoalveolar lavage fluid
(BAL) samples from ARDS patients showed the presence of
increased numbers of neutrophils6 as well as high
concentrations of elastase and collagenase.8 Furthermore,
ARDS patients’ BAL has enhanced neutrophil chemotactic
activity, and high concentrations of the neutrophil
chemotactic factor interleukin-8 have been reported.9
If neutrophils accumulate in the lungs early in the
development of ARDS, specific neutrophil chemotactic
signals should be detectable in vivo before lung injury is
evident clinically. Leukotriene B4 and C5a have neutrophil
chemotactic and activating properties in vitro, but the role of
leukotriene B4 in ARDS is uncertain,l&deg; and the lungs (and
pulmonary macrophages in particular) seem to produce
little C5a in experimental models of lung inflammation."
Among the family of cytokines whose primary functions
include neutrophil activation and chemotaxis, interleukin-8
is an important member; within the lungs it is principally
produced by macrophages.12 Although other cells may
make substantial contributions, alveolar macrophages can
express interleukin-8 mRNA within 60 min of stimulation
with lipopolysaccharide tumour necrosis factor, or
interleukin-1. These observations and the finding that
BAL from patients with ARDS shows biochemical
characteristics of this cytokine family suggest that
interleukin-8 is a candidate for the initiation and progression
of neutrophil-mediated events in ARDS. Circulating
plasma concentrations of mediators likely to be important in
the pathogenesis of ARDS (eg, C5a, endotoxin, tumour
necrosis factor) have not proved useful as predictors of
ARDS in at-risk patients. 14,15 We therefore included
measurement of interleukin-8 in BAL as well as in plasma.
Patients and methods
Patients presenting with three well-defined disorders
predisposing to ARDS were eligible. We studied 7 patients with
severe pancreatitis, who satisfied two or more of the established
prognostic criteria for pancreatitis ;16 samples from these patients
were obtained on day 1 of hospital admission. 16 patients with
severe multiple trauma, who required intubation in the accident and
emergency department, were also eligible for study enrolment. The
injury severity in this group was assessed by anatomical (injury
severity score) and physiological (revised trauma score) methods."
We also enrolled 6 patients with a clinical diagnosis of perforated
bowel, for whom surgical intervention was planned; the lung lavage
and blood sampling were done preoperatively when the patients
were under general anaesthesia. Consecutive at-risk patients were
enrolled at the Royal Infirrnary and the Western General Hospital,
Edinburgh. Patients with perforated bowel or pancreatitis gave
informed consent themselves; for those with multiple trauma
consent was obtained from relatives or guardians. In 7 further cases
consent for bronchoscopy was refused (2 of these patients
subsequently developed ARDS). The study was approved by the
Lothian Health Board Ethics Committee.
ARDS was defined by a lung injury score of more than 5.This
value was obtained by scoring, on a scale of 0-4, the extent of chest
radiograph infiltrates, pulmonary compliance, ratio of arterial
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Fig 1-interleukin-8 concentrations in BAL and-blood.
oxygen tension to inspired oxygen concentration, and positive end
expiratory pressure (PEEP) used. The lung injury score was
derived by dividing the total score by the number of criteria used.
In non-intubated patients a fibreoptic bronchoscope was
introduced through the nose after topical lignocaine anaesthesia of
the nasal passages and upper airway. In intubated patients, topical
lignocaine was not used and the bronchoscope was passed through
an indwelling endotracheal tube. The bronchoscope was wedged in
either the right middle lobe or the left lingular segment. Three 60 ml
volumes of saline (0-9% sodium chloride solution) were instilled
then gently aspirated immediately. On average 60% of instilled
fluid was recovered (range 40-85%). All bronchoscopy procedures
were done by one doctor (S. C. D.). Recovered fluid was stored at
4&deg;C until processing within 1 h. After straining through sterile
gauze to remove mucus, the fluid was centrifuged at 400 gat 4&deg;C for
10 min to recover cells. Total cell counts were done with a
haemocytometer. Samples of cells were pelleted onto glass slides
with a Cytospin 2 (Shandon Scientific, Cheshire, UK) and stained
with Diff-Quick (Merz-Dade AG, Dudingen, Switzerland), a
modified Wright-Giemsa stain. Differential counts were made by
counting 500 cells under oil immersion ( 100). The BAL
supernatant was respun at 1000 g for 10 min at 4&deg;C to remove
cellular debris and stored at 70&deg;C until assay for interleukin-8.
BAL cell cytospins were stained for intracellular interleukin-8 by
standard indirect immunohistochemical methods. An alkaline-
phosphatase-linked rabbit antibody to goat immunoglobulin was
used as second antibody. Confocal images of fluorescent staining
were obtained with a Zeiss LSM microscope (Oberkochen,
Germany).
At the time of venous sampling for clinical indications, 5 ml blood
was taken for study purposes. For trauma patients, this sample was
taken on initial presentation; for other patient groups it was taken on
day 1 of hospital admission. All blood samples were stored at 4&deg;C
until time of processing, which was within 1 h of collection. Blood
samples were centrifuged at 1000 g for 10 min at 4&deg;C. Plasma was
aspirated and stored at - 70&deg;C.
Extracellular immunoreactive interleukin-8 was quantified by a
modification of a double-ligand enzyme-linked immunosorbent
assay (ELISA).19 Rabbit antibody to interleukin-8 was bound to
Fig 2-lmmunohistochemical analysis and fluorescent
staining for interleukin-S within alveolar macrophages
from BAL samples on initial hospital presentation.
A= patient 1, who progressed to ARDS. B= patient 17, no ARDS,
x 1600
microtitre plates (Nunc Immuno-Plate I 96-F; Naperville, Illinois,
USA) by incubation (50 )il per well of 1 ng/mL antibody in 0-6
mmol/L sodium chloride, 0-26 mol/L boric acid, and 0-08 mol/L
sodium hydroxide pH 9-6) for 16 h at 4&deg;C. After this, and each other
step, the plates were washed four times with phosphate-buffered
saline (pH 75) containing 0-05% Tween 20. Non-specific binding
sites were blocked by incubation with 2% bovine serum albumin in
phosphate-buffered saline. Samples (50 Ld per well undiluted, 1/5,
and 1/10 dilutions of cell-free supernatant) were incubated in the
wells for 1 h at 37&deg;C, then labelled free antibody (biotinylated rabbit
antibody to interleukin-8, 3,5 ng/mL) was added and after 30 min
incubation, streptavidin-peroxidase conjugate (Bio-Rad
Laboratories, Richmond, California, USA) was added for a further
incubation of 30 min at 37&deg;C. Chromogen substrate (Bio-Rad) was
added and the plates were incubated at room temperature to the
desired extinction. The reaction was terminated with 50 )iL per well
of 3 mol/L sulphuric acid. Plates were read at 490 mn in an ELISA
reader. Standards were 1/2 log dilutions of recombinant
interleukin-8, from 1 pg/mL to 100 ng/mL. This method
consistently detected interleukin-8 concentrations above 10 pg/mL.
Comparisons of patient groups were made by non-parametric
methods-the Mann-Whitney test or Spearman rank correlation
coefficient, where appropriate. Significance was defined as p < 0-05.
Results
Samples obtained from the 16 multiple trauma patients
were taken on average 20 (range 07-3-3) h after the trauma
episode. The range of injury severity scores for this group of
patients was 16-54. No significant correlation was found
between the initial interleukin-8 concentration found in
blood and BAL samples and injury severity score (p = 0-35
and p-094).
Among the pancreatitis patients, 4 had gallstone-related
disease and 3 alcohol-related disease. The duration of
symptoms before sampling was 34-3 (range 12-72) h for
pancreatitis patients and 33-0 (range 6-72) h for patients
with perforated bowel. Of the 29 patients enrolled, 7
subsequently developed ARDS. 10 of the 29 patients
enrolled were smokers; 3 of the 7 who progressed to ARDS
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and 7 of 22 who did not. 3 of the 7 patients with ARDS died
compared with 5 of the 22 patients without ARDS. Clinical
details are given in the table.
The mean BAL concentration of interleukin-8 was
significantly higher for the ARDS group than for the
non-ARDS group (table, fig 1). No significant relation to
ARDS development was found for blood interleukin-8
measurements (table, fig 1). Immunocytochemical tests for
interleukin-8 showed significantly greater staining of
alveolar macrophages from patients who subsequently
progressed to ARDS than of macrophages from non-ARDS
patients (fig 2).
Discussion
Our findings suggest that BAL concentrations of
interleukin-8 may have prognostic value for the
development of ARDS in at-risk patients. In view of the
complex nature of the inflammatory process in patients with
multiple trauma and other disorders predisposing to ARDS,
it is not surprising that the search for an early common
predictive marker from blood samples has been
unsuccessful.lo&deg;14&deg;ls Most previous studies have enrolled
patients after admission to intensive care units, when the
cellular process of ARD S has been under way for some time.
This study was designed to seek evidence for early
predictive inflammatory events in blood and in the target
organ, the lungs, by studying BAL samples from at-risk
patients enrolled at hospital presentation.
Excessive inflammatory-cell activation, especially
neutrophil activation, has been implicated in ARDS.3 6--8 At
some stage during the evolution of lung injury, local
chemoattractants must be generated to drive neutrophil
recruitment. Interleukin-8 is a potent and specific
neutrophil chemotactic factor,20 which also induces
transendothelial migration, rises in cytoplasmic calcium,
release of reactive oxygen metabolites, and neutrophil
degranulation.21-23 The potential importance of interleukin-
8 in the pathogenesis of inflammatory disease has been
suggested by findings of increased synthesis by
mononuclear cells in rheumatoid joints24 and in idiopathic
pulmonary fibrosis.25 Miller et al9 have suggested that
interleukin-8 has an important role in ARDS disease
pathogenesis. We detected high concentrations of
interleukin-8 in BAL from trauma patients, some within 1 h
of injury. Patients who progressed to ARDS had much
higher BAL interleukin-8 concentrations than patients who
did not develop ARDS. 6 of the 7 patients who progressed to
ARDS had initial BAL interleukin-8 concentrations above
0-200 ng/mL; the 22 non-ARDS patients all had values
below 0-150 ng/mL. Interleukin-8 concentrations in initial
blood samples did not predict ARDS development.
Previous reports of BAL in healthy non-smokers describe
a percentage yield of neutrophils of between 0 and 12% 26
The average yield of neutrophils from our early lung lavages
of patients who subsequently progressed to ARDS was only
5%. This finding suggests that our BAL samples were
obtained at a very early stage of ARDS pathogenesis, when
interleukin-8 has increased but before substantial numbers
of neutrophils have migrated into the airspaces.
The cellular source of the interleukin-8 in BAL is
uncertain. Interleukin-8 was first isolated from the culture
supernatants of lipopolysaccharide-stimulated monocytes
in vitro.12 Other cell types subsequently identified as being
able to secrete this cytokine include endothelial cells,
neutrophils, lymphocytes, and epithelial cells.19 27-29
Although there are several possible sources, other studies
show that lung macrophages have the potential to produce
large amounts of interleukin-8.
By immunohistochemistry we have obtained preliminary
evidence of more interleukin-8 within alveolar macrophages
from patients who progressed to ARDS than in alveolar
macrophages from patients who did not (fig 2).
On the present criteria, the diagnosis of ARDS is not
usually made before the patient reaches the intensive care
unit, often days after the provoking insult. Our findings
suggest that measurement of interleukin-8 in BAL of at-risk
patients could enable early identification of those likely to
progress to ARDS. Future therapeutic interventions could
then be aimed specifically at a subgroup of very-high-risk
patients. Our findings further implicate neutrophils in most
cases of ARDS and emphasise the local generation of
interleukin-8 and its subsequent effects as possible
therapeutic targets for attempts to attenuate or abort the
ARDS process before it progresses to full-blown lung
injury.
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Detection of rifampicin-resistance mutations in
Mycobacterium tuberculosis
Control of tuberculosis is threatened by
widespread emergence of drug resistance in
Mycobacterium tuberculosis. Understanding the
molecular basis of resistance might lead to
development of novel rapid methods for diagnosing
drug resistance. We set out to determine the
molecular basis of resistance to rifampicin, a major
component of multidrug regimens used for treating
tuberculosis.
Resistance to rifampicin involves alterations of
RNA polymerase. The gene that encodes the RNA
polymerase subunit &bgr; (rpoB) was cloned. Sequence
information from this gene was used to design
primers for direct amplification and sequencing of a
411 bp rpoB fragment from 122 isolates of
M tuberculosis. Mutations involving 8 conserved
aminoacids were identified in 64 of 66 rifampicin-
resistant isolates of diverse geographical origin, but
in none of 56 sensitive isolates. All mutations were
clustered within a region of 23 aminoacids. Thus,
substitution of a limited number of highly conserved
aminoacids encoded by the rpoB gene appears
to be the molecular mechanism responsible for
"single step" high-level resistance to rifampicin in
M tuberculosis. This information was used to
develop a strategy (polymerase chain reaction-
single-strand conformation polymorphism) that
allowed efficient detection of all known rifampicin-
resistant mutants.
These findings provide the basis for rapid
detection of rifampicin resistance, a marker of
multidrug-resistant tuberculosis.
Introduction
Resistance of Mycobacterium tuberculosis to
antituberculous drugs has emerged as a major public-health
threat, particularly among patients infected with human
immunodeficiency virus.1-5 Rifampicin is a key component
of therapeutic regimens; therefore, patients in whom
resistance to this drug develops have a poor outlook,
particularly if rifampicin resistance is associated with
resistance to other antituberculous drugs
Development of resistance to rifampicin in M tuberculosis
follows a "single-step" high-level resistance pattern9
Mutants arise spontaneously in strains not exposed
previously to the antibiotic at a rate of one mutation per
10 -7 to 10 - 8 organisms.9,10 Resistance has been attributed
to changes in RNA polymerase," but the precise molecular
mechanism has not been established in mycobacteria. The
structural and functional organisation of RNA polymerases
is conserved among bacteria.12 In Escherichia coli resistance
to rifampicin is associated with specific nucleicacid
substitutions in the gene encoding for RNA polymerase
subunit P (rpoB).13 To evaluate the moleclar mechanism of
resistance to rifampicin in Af tuberculosis, we identified,
cloned, and partly sequenced the rpoB of this organism, and
compared this sequence with those of polymerase chain
reaction (PCR) generated fragments of the rpoB from 122
clinical isolates of rifampicin resistant and sensitive
M tuberculosis. We have used this information to develop a
novel strategy for rapid detection of rifampicin resistance.
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